This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CDP791
Description: CDP-791 is a novel, investigational antibody targeting the vascular endothelial growth factor receptor-2 (VEGFR-2) that is currently being developed by UCB. VEGFR-2 is known to regulate the formation of blood vessels in tumors, allowing cancer cells to receive nutrients andmaintain growth. CDP-791 takes the novel approach of targeting and blocking VEGFR-2 on blood vessel cells with a PEGylated diFab antibody and thus interferes with the development of tumor vasculature. This mechanism has been shown to interfere with tumor vasculature in preclinical models.
Deal Structure: ImClone Systems Incorporated and UCB announced in August 2005 a worldwide strategic partnership for the development and commercialization of CDP-791. Under terms of the agreement, UCB and ImClone Systems will share equally all agreed upon development costs for CDP-791 as well as worldwide profits derived from its commercialization in indications jointly pursued by the parties. ImClone Systems will also receive an incremental single-digit royalty on net worldwide sales for such labeled indications. ImClone Systems has exclusive commercializationrights to CDP-791 in North America, with UCB receiving such rights in Europe, Japan, and the rest of the world.
In February 2007, ImClone opted-out of its development agreement with UCB for CDP-791 to refocus its resources on developing IMC-1121B. Under the terms of its agreement with UCB, ImClone Systems has the right to receive a royalty based on CDP-791 sales, should the antibody be commercialized, and UCB retains freedom to operate...See full deal structure in Biomedtracker
Partners: Nektar Therapeutics Eli Lilly & Company
CDP 791 News
Additional information available to subscribers only: